SCHEMBL805555

SCHEMBL805555

CCc1cc(Nc2cnnc(-c3cccc(C)c3)n2)n[nH]1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITK Q08881 1/20 0.40
GRK6 P43250 8/20 0.38
AURKA O14965 5/20 0.38
CYP1A2 P05177 2/20 0.38
CYP2C9 P11712 1/20 0.38
MAP3K5 Q99683 1/20 0.37
IGF1R P08069 2/20 0.37
FGFR1 P11362 1/20 0.37
KDR P35968 1/20 0.37
IDO1 P14902 1/20 0.36
METAP2 P50579 1/20 0.36
NTRK1 P04629 1/20 0.36
EGFR P00533 1/20 0.36
CCNA2 P20248 1/20 0.36
CDK2 P24941 1/20 0.36
CCNA1 P78396 1/20 0.36
RAB9A P51151 1/20 0.35
HEXA P06865 1/20 0.35
HEXB P07686 1/20 0.35
SRC P12931 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL801762 0.88 GRK6 (0.41) ITKGRK6AURKAIGF1RIDO1
SCHEMBL801772 0.73 ITK (0.52) ITKAURKAEGFRRAB9ASRC
SCHEMBL801771 0.71 RET (0.40) GRK6AURKAIGF1RFGFR1KDR
SCHEMBL14985490 0.69 IDO1 (0.50) CYP2C9IDO1METAP2RAB9AALDH1A1
SCHEMBL4172285 0.68 BRAF (0.48) ITKAURKAIDO1METAP2SRC
SCHEMBL13945073 0.65 ITK (0.45) ITKAURKAIGF1REGFRSRC
SCHEMBL4205034 0.63 AURKA (0.60) ITKAURKAFGFR1KDRNTRK1
SCHEMBL802002 0.63 ITK (0.63) ITKAURKAIGF1RSRCEIF2AK2
SCHEMBL3849950 0.62 GRK6 (0.42) GRK6AURKAIGF1RNTRK1CCNA2
SCHEMBL13663484 0.62 JAK2 (0.49) ITKAURKAIGF1RKDREGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2012-03-22 US disclosed
US-20100256170-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-10-07 US disclosed
US-7390815-B2 Pyrazole compounds useful as protein kinase inhibitors VERTEX PHARMACEUTICALS INCORPORATED (US) 2008-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256170-A1 PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, CDK3, GSK3A ITK 1149/4885GRK6 766/4885AURKA 7/4885
US-20120071657-A1 TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS GSK3B, GSK3A, CDK19 ITK 1124/4885GRK6 576/4885AURKA 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.